Cargando…
3-(5-Phenyl-4-phenylsulfonyl-1-p-tolyl-1H-pyrazol-3-yl)-1,2-dihydroquinoxaline
In the crystal structure of the title compound, C(30)H(24)N(4)O(2)S, the dihydroquinoxaline fused-ring system is disordered over three orientations in a 0.358 (2):0.318 (3):0.324 (3) ratio; the mean planes of the non-H atoms of the disorder components are aligned at 4.0 (3), 11.8 (4) and 41.7 (2)°...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
International Union of Crystallography
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3052037/ https://www.ncbi.nlm.nih.gov/pubmed/21522440 http://dx.doi.org/10.1107/S1600536811005940 |
_version_ | 1782199612237414400 |
---|---|
author | Abdel-Aziz, Hatem A. Bari, Ahmed Ng, Seik Weng |
author_facet | Abdel-Aziz, Hatem A. Bari, Ahmed Ng, Seik Weng |
author_sort | Abdel-Aziz, Hatem A. |
collection | PubMed |
description | In the crystal structure of the title compound, C(30)H(24)N(4)O(2)S, the dihydroquinoxaline fused-ring system is disordered over three orientations in a 0.358 (2):0.318 (3):0.324 (3) ratio; the mean planes of the non-H atoms of the disorder components are aligned at 4.0 (3), 11.8 (4) and 41.7 (2)° with respect to the pyrazole ring. The rings of the phenyl and tolyl substituents are aligned at 64.0 (1) and 43.7 (1)° with respect to the pyrazole ring. Weak intermolecular C—H⋯O hydrogen bonding links the molecules, forming supramolecular chains running along the a axis. |
format | Text |
id | pubmed-3052037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | International Union of Crystallography |
record_format | MEDLINE/PubMed |
spelling | pubmed-30520372011-04-26 3-(5-Phenyl-4-phenylsulfonyl-1-p-tolyl-1H-pyrazol-3-yl)-1,2-dihydroquinoxaline Abdel-Aziz, Hatem A. Bari, Ahmed Ng, Seik Weng Acta Crystallogr Sect E Struct Rep Online Organic Papers In the crystal structure of the title compound, C(30)H(24)N(4)O(2)S, the dihydroquinoxaline fused-ring system is disordered over three orientations in a 0.358 (2):0.318 (3):0.324 (3) ratio; the mean planes of the non-H atoms of the disorder components are aligned at 4.0 (3), 11.8 (4) and 41.7 (2)° with respect to the pyrazole ring. The rings of the phenyl and tolyl substituents are aligned at 64.0 (1) and 43.7 (1)° with respect to the pyrazole ring. Weak intermolecular C—H⋯O hydrogen bonding links the molecules, forming supramolecular chains running along the a axis. International Union of Crystallography 2011-02-23 /pmc/articles/PMC3052037/ /pubmed/21522440 http://dx.doi.org/10.1107/S1600536811005940 Text en © Abdel-Aziz et al. 2011 http://creativecommons.org/licenses/by/2.0/uk/ This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited. |
spellingShingle | Organic Papers Abdel-Aziz, Hatem A. Bari, Ahmed Ng, Seik Weng 3-(5-Phenyl-4-phenylsulfonyl-1-p-tolyl-1H-pyrazol-3-yl)-1,2-dihydroquinoxaline |
title | 3-(5-Phenyl-4-phenylsulfonyl-1-p-tolyl-1H-pyrazol-3-yl)-1,2-dihydroquinoxaline |
title_full | 3-(5-Phenyl-4-phenylsulfonyl-1-p-tolyl-1H-pyrazol-3-yl)-1,2-dihydroquinoxaline |
title_fullStr | 3-(5-Phenyl-4-phenylsulfonyl-1-p-tolyl-1H-pyrazol-3-yl)-1,2-dihydroquinoxaline |
title_full_unstemmed | 3-(5-Phenyl-4-phenylsulfonyl-1-p-tolyl-1H-pyrazol-3-yl)-1,2-dihydroquinoxaline |
title_short | 3-(5-Phenyl-4-phenylsulfonyl-1-p-tolyl-1H-pyrazol-3-yl)-1,2-dihydroquinoxaline |
title_sort | 3-(5-phenyl-4-phenylsulfonyl-1-p-tolyl-1h-pyrazol-3-yl)-1,2-dihydroquinoxaline |
topic | Organic Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3052037/ https://www.ncbi.nlm.nih.gov/pubmed/21522440 http://dx.doi.org/10.1107/S1600536811005940 |
work_keys_str_mv | AT abdelazizhatema 35phenyl4phenylsulfonyl1ptolyl1hpyrazol3yl12dihydroquinoxaline AT bariahmed 35phenyl4phenylsulfonyl1ptolyl1hpyrazol3yl12dihydroquinoxaline AT ngseikweng 35phenyl4phenylsulfonyl1ptolyl1hpyrazol3yl12dihydroquinoxaline |